SpineGuard Strengthens Its IP With the Grant of Three New Patents
27 Avril 2020 - 6:00PM
Business Wire
- Grant of “multi-electrodes” patent in the USA
- Grant of two “real time” patents in Singapore and
Russia
- Broadening of the portfolio with a total of 71 patents in 17
countries
Regulatory News:
SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an
innovative company that deploys its DSG® (Dynamic Surgical
Guidance) sensing technology to secure and streamline the placement
of bone implants, announces today the grant of three new patents in
the United States, Singapore and Russia.
The “multi-electrodes” patent granted in the United States
describes the implementation of the DSG technology via multiple
electrodes in order to perform 3D electromagnetic mapping of the
operated region.
Furthermore, two patents granted in Singapore and in Russia
extend until 2035 the protection of the DSG technology (Dynamic
Surgical Guidance) for guidance in bone via tissue conductivity
measurement, in-situ, in real time and without utilization of
X-rays.
Stéphane Bette, Deputy CEO and co-founder of SpineGuard,
said: “SpineGuard pursues innovation for securing and
streamlining the placement of implants in bone. The new
“multi-electrodes” patent, taken in combination with our new
interface “DSG Connect” and our intellectual property in robotic
applications, paves the way for the development of new disruptive
products in strategic markets. The United States are by far the
first market worldwide for medical devices, hence a major benefit
in holding key patents there. The two “real time” patents granted
in Singapore and in Russia strengthen the already solid protection
of our core technology DSG and extend it until 2035. Our IP
portfolio now entails a total of 71 patents divided into 13
families. They cover all the main global geographies of our market.
This step forward provides additional and increased value for our
shareholders and is useful in the context of the current
discussions for establishing strategic structuring alliances.”
Annual Shareholders Meeting of 14 May 2020
In compliance with recent legislation (bill of 23 March 2020 to
respond to COVID-19 and decree dated 25 March) and per the
recommendations of the French SEC (Autorité des Marchés Financiers
or AMF), SpineGuard confirms that the Annual Ordinary and
Extraordinary Shareholders Meeting will take place on May 14, 2020
at 8:45 am (CEST), yet it will not be held in public. It is hereby
reminded that AMF strongly encourages the shareholders to vote,
such right being a fundamental prerogative of each shareholder.
Such right shall be exercised through a vote by proxy in case of a
non-publicly held shareholders meeting and, except for particular
cases, prior to the said shareholders meeting.
As of the date of this news release, the logistics details are
being worked out for the Shareholders meeting to be held in perfect
conditions with the on-going pandemic situation. The Shareholders
Meeting will be held via web conference. The shareholders
presentation will be released on the company’s web site at 8:45 am
(CEST) on the day of the meeting at
https://www.spineguard.com/fr/investisseurs/documentation/
Connection details to the web conference will be provided at a
later date.
Questions will be possible using the available chat during the
conference or be sent in advance at either of
investors@spineguard.com or spineguard@newcap.eu
About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and
Stéphane Bette, SpineGuard is an innovative company deploying its
proprietary radiation-free real time sensing technology DSG®
(Dynamic Surgical Guidance) to secure and streamline the placement
of implants in the skeleton. SpineGuard designs, develops and
markets medical devices that have been used in over 75,000 surgical
procedures worldwide. Fifteen studies published in peer-reviewed
scientific journals have demonstrated the multiple benefits DSG®
offers to patients, surgeons, surgical staff and hospitals.
Building on these solid fundamentals and several strategic
partnerships, SpineGuard has expanded its technology platform in a
disruptive innovation: the « smart » pedicle screw launched late
2017 and is broadening the scope of applications in dental
implantology and surgical robotics. DSG® was co-invented by Maurice
Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem,
Biomedical Engineer.
For further information, visit www.spineguard.com
Disclaimer
The SpineGuard securities may not be offered or sold in the
United States as they have not been and will not be registered
under the Securities Act or any United States state securities
laws, and SpineGuard does not intend to make a public offer of its
securities in the United States. This is an announcement and not a
prospectus, and the information contained herein does and shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of the securities referred to herein in
the United States in which such offer, solicitation or sale would
be unlawful prior to registration or exemption from
registration.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200427005469/en/
SpineGuard Pierre Jérôme CEO & Chairman Tel.: +33 1
45 18 45 19 p.jerome@spineguard.com
SpineGuard Manuel Lanfossi CFO Tél.: +33 1 45 18 45 19
m.lanfossi@spineguard.com
NewCap Investor Relations & Financial
Communication Mathilde Bohin / Pierre Laurent Tel.: +33 1 44 71 94
94 spineguard@newcap.eu
Spineguard (EU:ALSGD)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Spineguard (EU:ALSGD)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024